No Data
No Data
Nexalin America Selected to Join the National Traumatic Brain Injury Registry Coalition to Propel TBI Awareness and Research Efforts
HOUSTON, TX, May 22, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the "Company" or "Nexalin") (Nasdaq: NXL; NXLIW) is pleased to announce its new division, Nexalin America, has been selected t
Nexalin Technology First Quarter 2024 Earnings: US$0.14 Loss per Share (Vs US$0.10 Loss in 1Q 2023)
10-Q: Quarterly report
Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on May 23
HOUSTON, May 09, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the "Company" or "Nexalin") (NASDAQ:NXL, NXLIW)) is pleased to invite investors to a webinar on May 23, 2024, at 4:15 p.m. ET. The exclusive event,
Nexalin Technology Has Received A Notice Of Allowance For Its U.S. Patent Application 18/342,590 Titled "Transcranial Alternating Current Dynamic Frequency Stimulation (TACS) Method For Alzheimers And Dementia"
Nexalin Technology Has Received A Notice Of Allowance For Its U.S. Patent Application 18/342,590 Titled "Transcranial Alternating Current Dynamic Frequency Stimulation (TACS) Method For Alzheimers And
Express News | Nexalin Technology Regains Compliance With Nasdaq Continued Listing Requirements
No Data